WEAR study: adherence to wearable activity trackers in RA Something that is consistent across all wearable studies is low adherence Here under 50% for PRO + tracking In an already selected population! To implement, we need to make this better? ABSTRACT 0344 @RheumNow #ACR23 https://t.co/csVZlzABGt

Year in Review: Dr. P Seo ⭐️Does Pizza consumption favor improved dz activity in RA? If in Italy ➡️ 365 pts w/RA in Milan: 18-65 yo w/ >3 mo dz ➡️Ate 1/2 a pizza > 1x/wk w/ decr in dz activity (SDAI⬇️: -3.6) ➡️Mozzarella & olive oil showed beneficial effects #ACR23 @RheumNow https://t.co/qZTzThI39e

Towards more personalised care in rheumatoid arthritis #ACR23 @RheumNow https://t.co/roxtcX8QHI

RA as a young woman used to mean kids were only a distant thought. Japanese RA pts n=280 asked whether RA onset meant wanting fewer children & why. Confidence improving across the board over time. We want to give our RA pts choices to live their life! #ACR23 ABST0473 @RheumNow https://t.co/OHZM2J5qxS

Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️ABBV-3373 ➡️ Adalimumab (ADA) + GC receptor modulator vs ADA ➡️ Phase II, 48 pts, previously failed MTX ➡️ Wk 12: better DAS28-CRP, ACR20/70 🚩71% of responders stayed in remission after switch to PBO #ACR23 @RheumNow

Difficult to treat RA is not an homogeneous group! Trajectory analysis 60months shows 4 different clusters Cluster 2 = 1/3 of patients, do better but never reach LDA. The ones Fibromyalgia, OA and other conditions blurring assessment? #Abstract0382 #ACR23 @RheumNow https://t.co/dxxS7vCcMt

Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️Peresolimab ➡️ stimulates PD1 ➡️ Phase II, 98 pts ➡️ tx-resistant to other therapies including biologics ➡️ Wk 12: better DAS28, ACR20, not ACR 50/70 #ACR23 @RheumNow

YR in Review: Dr. Seo 🚩GLORIA Trial RA pts > 65yo: prednisolone 5 mg/d x 2 yrs vs PBO + std care ➡️decr dz activity (DAS ⬇️0.37) but 24% incr ADE 🚩Extension: ➡️Tapered off pred over 3m and.. ⭐️NO ADRENAL INSUFF But, small incr in dz activity (DAS ⬆️0.23) #ACR23 @RheumNow https://t.co/YQbS6C8ZT5

It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA. Why is it hard? I guess: - theory ≠ practice - too many other factors - it's too easy not to Yet I hope/believe, one day we'll do better. #ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN

If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year? US Medicare data 2008-17 n=33,373 only 30% have a DMARD on file (of which bDMARD <10%) >5% on PNL alone Do we hate old people with RA?😔 @JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0

I underestimated how much joy not-bankrupting our healthcare system would bring me ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party @RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd

Contributing Factors for Difficult-to-Treat RA using Natural Language Processing (NLP): joint erosions (OR 2.97 CI95% [2.17; 4.08], p< 0.001) , higher disease activity (median DAS28 3.16 vs 2.89) associated with D2T, Bergier Abst#0383 #ACR23 @RheumNow https://t.co/KARxoa2Z7H

COVID boosters in RA patients: getting the job done (versus healthy controls, irrespective of non-withheld DMARDs excluding ritux) @UChicagoMed #ACR23 ABST0416 @RheumNow https://t.co/HVRjC4dauw

Can a picture tell a RA swollen joint? (would be super useful for telehealth/remote monitor if so) It's not prime time yet, but following with interest: using photos to pick up on skin folds/joint swelling Fascinating, but let's see it vs MRI, clinical #ACR23 ABST0402 @RheumNow https://t.co/TFKiD5J4c8

Year in Review by Dr. P Seo NORD-STAR trial: ⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results ➡️tx-naive, all got MTX ➡️mod-sev dz activity ➡️randomized to 48 wks therapy #ACR23 @RheumNow https://t.co/vy2uYuyOse